IPOs: Enanta Wows While Tetraphase Gets The Job Done
This article was originally published in The Pink Sheet Daily
Executive Summary
A pair of biotech IPOs priced on March 20 with mixed results. Hepatitis C developer Enanta got a warm reception from investors looking to tap into what has been a lucrative sector. But antibiotics company Tetraphase priced below its range and traded flat.
You may also be interested in...
Tetraphase On Track For Antibiotic Submission In 2015
The biotech reported positive topline data from an interim analysis of its second Phase III trial that puts it on track to release data, submit and potentially see approval next year.
Tetraphase On Track For Antibiotic Submission In 2015
The biotech reported positive topline data from an interim analysis of its second Phase III trial that puts it on track to release data, submit and potentially see approval next year.
Biopharma IPOs Start to Gear Up For 2013 After a Lull
Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.